Annovis Bio to Present at The LD 500 Virtual Conference
LOS ANGELES, CA / ACCESSWIRE / August 25, 2020 / Annovis Bio Inc. (NYSE American:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that it will be presenting at the LD 500 investor conference on Tuesday, September 1 at 9:20 AM EDT. Annovis Bio CEO Maria Maccecchini, Ph.D. will be presenting.
"Annovis Bio is at a very exciting stage right now with two Phase 2 trials underway," commented Dr. Maccecchini. "I look forward to sharing our unique and promising approach to treating Alzheimer's, Parkinson's, and other neurodegenerative diseases with the LD 500 audience."
Register here: https://ld-micro-conference.events.issuerdirect.com/
"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space," stated Chris Lahiji, Founder of LD.
The LD 500 will take place on September 1st through the 4th.
View Annovis Bio's profile here: http://www.ldmicro.com/profile/ANVS
Profiles powered by LD Micro - News Compliments of Accesswire
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.
What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.
The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
Contact:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio via LD Micro
View source version on accesswire.com:
https://www.accesswire.com/603213/Annovis-Bio-to-Present-at-The-LD-500-Virtual-Conference
